Abstract
We have recently shown that oral consumption of green tea polyphenols inhibits prostate carcinogenesis in transgenic mouse model of prostate cancer and suggested that induction of apoptosis in prostate cancer cells is responsible for these effects. Much of the chemopreventive effects of green tea are attributed to its major polyphenolic constituent (−) epigallocatechin-3-gallate (EGCG). In the present study, we report that EGCG-induced apoptosis in human prostate carcinoma LNCaP cells is mediated via modulation of two related pathways: (a) stabilization of p53 by phosphorylation on critical serine residues and p14ARF-mediated downregulation of murine double minute 2(MDM2) protein, and (b) negative regulation of NF-κB activity, thereby decreasing the expression of the proapoptotic protein Bcl-2. EGCG-induced stabilization of p53 caused an upregulation in its transcriptional activity, thereby resulting in activation of its downstream targets p21/WAF1 and Bax. Thus, EGCG had a concurrent effect on two important transcription factors p53 and NF-κB, causing a change in the ratio of Bax/Bcl-2 in a manner that favors apoptosis. This altered expression of Bcl-2 family members triggered the activation of initiator capsases 9 and 8 followed by activation of effector caspase 3. Activation of the caspases was followed by poly (ADP-ribose) polymerase cleavage and induction of apoptosis. Taken together, the data indicate that EGCG induces apoptosis in human prostate carcinoma cells by shifting the balance between pro- and antiapoptotic proteins in favor of apoptosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- EGCG:
-
(−)-epigallocatechin-3-gallate
- PARP:
-
poly (ADP-ribose) polymerase
- Ac-DEVD-AFC:
-
N-acetyl-Asp-Glu-Val-Asp-AFC (7-amino-4-trifluoromethylcoumarin)
- adriamycin:
-
ADR
- MDM2:
-
murine double minute 2
References
Agarwal ML, Taylor WR, Chernov MV, Chernova OB and Stark GR . (1998). J. Biol. Chem., 273, 1–4.
Ahmad N, Feyes DK, Nieminen AL, Agarwal R and Mukhtar H . (1997). J. Natl. Cancer Inst., 89, 1881–1886.
Ahmad N, Gupta S and Mukhtar H . (2000). Arch. Biochem. Biophys., 376, 338–346.
Bates S and Vousden KH . (1999). Cell. mol. Life Sci., 55, 28–37.
Budram-Mahadeo V, Morris PJ and Latchman DS . (2002). Oncogene, 21, 6123–6131.
Burns TF, Bernhard EJ and El-Deiry WS . (2001). Oncogene, 20, 4601–4612.
Chen C, Edelstein LC and Gelinas C . (2000). Mol. Cell. Biol., 20, 2687–2695.
Chen ZP, Schell JB, Ho CT and Chen KY . (1998). Cancer Lett., 129, 173–179.
Conney AH, Lu Y, Lou Y, Xie J and Huang M . (1999). Proc. Soc. Exp. Biol. Med., 220, 229–233.
Dumaz N and Meek DW . (1999). EMBO J., 18, 7002–7010.
El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang YS, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW and Vogelstein B . (1994). Cancer Res., 54, 1169–1174.
Fotedar R, Brickner H, Saadatmandin N, Rousselle T, Diederich L, Munshi A, Jung B, Reed JC and Fotedar A . (1999). Oncogene, 18, 3652–3658.
Gartel AL and Tyner AL . (2002). Mol. Cancer Ther., 1, 639–649.
Gupta S, Ahmad N, Nieminen AL and Mukhtar H . (2000). Toxicol. Appl. Pharmacol., 164, 82–90.
Gupta S, Hastak K, Ahmad N, Lewin JS and Mukhtar H . (2001). Proc. Natl. Acad. Sci. USA, 98, 10350–10355.
Gupta S, Hussain T and Mukhtar H . (2003). Arch. Biochem. Biophys., 410, 177–185.
Jackson MW, Lindstrom MS and Berberich SJ . (2001). J Biol. Chem., 276, 25336–25341.
Kubbutat MH, Jones SN and Vousden KH . (1997). Nature, 387, 299–303.
Kuo PL and Lin CC . (2003). J. Biomed. Sci., 10, 219–227.
Levites Y, Amit T, Youdim MB and Mandel S . (2002). J. Biol. Chem., 277, 30574–30580.
Miyashita T, Harigai M, Hanada M and Reed JC . (1994). Cancer Res., 54, 3131–3135.
Miyashita T and Reed JC . (1995). Cell, 80, 293–299.
Otsuka T, Ogo T, Eto T, Asano Y, Suganuma M and Niho Y . (1998). Life Sci., 63, 1397–1403.
Pianetti S, Guo S, Kavanagh KT and Sonenshein GE . (2002). Cancer Res., 62, 652–655.
Sheikh MS and Fornace Jr AJ . (2000). J. Cell Physiol., 182, 171–181.
Sherr CJ . (2001). Nat. Rev. Mol. Cell Biol., 2, 731–737.
Shibata MA, Yoshidome K, Shibata E, Jorcyk CL and Green JE . (2001). Cancer Gene Ther., 8, 23–35.
Shieh SY, Ikeda M, Taya Y and Prives C . (1997). Cell, 91, 325–334.
Sizemore N, Leung S and Stark GR . (1999). Mol. Cell. Biol., 19, 4798–4805.
Tamatani M, Che YH, Matsuzaki H, Ogawa S, Okado H, Miyake S, Mizuno T and Tohyama M . (1999). J. Biol. Chem., 274, 8531–8538.
Tao W and Levine AJ . (1999). Proc. Natl. Acad. Sci. USA, 96, 6937–6941.
Tohyama M . (1999). Biol. Chem., 274, 8531–8538.
Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D and Miyamoto S . (1995). Genes Dev., 9, 2723–2735.
Vogelstein B and Kinzler KW . (2001). Nature, 412, 865–866.
Vogelstein B, Lane D and Levine AJ . (2000). Nature, 408, 307–310.
Vousden KH . (2002). Biochim. Biophys. Acta., 1602, 47–59.
Vousden KH and Lu X . (2002). Nat .Rev. Cancer., 2, 594–604.
Weber JD, Taylor LJ, Roussel MF, Sherr CJ and Bar-Sagi D . (1999). Nat. Cell. Biol., 1, 20–26.
Webster GA and Perkins ND . (1999). Mol. Cell. Biol., 19, 3485–3495.
Weisburger JH . (1999). Proc. Soc. Exp. Biol. Med., 220, 271–275.
Wu X and Deng Y . (2002). Front Biosci., 7, d151–d156.
Yang CS, Chung JY, Yang G, Chhabra SK and Lee MJ . (2000). J. Nutr., 130, 472S–478S.
Yang GY, Liao J, Kim K, Yurkow EJ and Yang CS . (1998). Carcinogenesis, 19611–19616.
Zimmermann KC, Bonzon C and Green DR . (2001). Pharmacol. Ther., 92, 57–70.
Acknowledgements
We sincerely thank Dr George Stark (Cleveland Clinic Foundation, Cleveland, OH, USA) for his suggestions, encouragement and help. This work was supported by United States Public Health Services Grant RO1 CA 78809.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hastak, K., Gupta, S., Ahmad, N. et al. Role of p53 and NF-κB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 22, 4851–4859 (2003). https://doi.org/10.1038/sj.onc.1206708
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206708
Keywords
This article is cited by
-
Flavonoids target different molecules of autophagic and metastatic pathways in cancer cells
Cancer Cell International (2023)
-
An update of Nrf2 activators and inhibitors in cancer prevention/promotion
Cell Communication and Signaling (2022)
-
EGCG binds intrinsically disordered N-terminal domain of p53 and disrupts p53-MDM2 interaction
Nature Communications (2021)